Reducing harmful brain inflammation after organophosphate exposure

Project 1: Reduction of Pro-Inflammatory Signaling

NIH-funded research University of California at Davis · NIH-11174351

Trying anti-inflammatory medicines given with standard emergency care to help people who survive severe organophosphate (nerve-agent or pesticide) poisoning avoid long-term seizures and memory problems.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of California at Davis NIH-funded
Lab location1 site (Davis, United States)
Project IDNIH-11174351 on NIH RePORTER

What this research studies

The team uses a well-established rat model that mimics the seizures and memory loss seen after acute organophosphate poisoning. They will give drugs that block COX-2 or inhibit soluble epoxide hydrolase (sEH) alongside standard emergency treatments to shift brain lipid signals away from inflammation. Researchers will track seizure recurrence, memory performance, and markers of brain inflammation for months and analyze brain lipids to see which treatments promote recovery. The goal is to identify drug combinations that could be added to current care to prevent chronic neurological problems after poisoning.

Who could benefit from this research

Good fit: People who survived acute organophosphate (nerve-agent or pesticide) poisoning and are at risk for ongoing seizures or memory problems would be the group most likely to benefit from these findings.

Not a fit: People whose epilepsy or memory problems are caused by other conditions (such as genetic epilepsy, traumatic brain injury unrelated to organophosphate exposure, or Alzheimer’s disease) may not benefit from these specific treatments.

Why it matters

Potential benefit: If successful, this approach could lower the chance of long-term seizures and memory loss after acute organophosphate poisoning by adding anti-inflammatory drugs to current care.

How similar studies have performed: Anti-inflammatory strategies like COX-2 inhibition and sEH inhibition have shown benefit in animal models of epilepsy and brain injury, but their use specifically after organophosphate poisoning is still at the preclinical stage.

Where this research is happening

Davis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer's disease model
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.